Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
Epistemonikos ID: 4ad87c4fe0c0f6f730b7a4bdf19a62de023dbeca
First added on: Feb 19, 2024